GlobeNewswire: Sensus Healthcare, Inc. Contains the last 10 of 102 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:36:45ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/14/2846688/0/en/Sensus-Healthcare-to-Participate-in-the-36th-Annual-Roth-Conference.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare to Participate in the 36th Annual Roth Conference2024-03-14T20:05:00Z<![CDATA[Management will discuss its new “Fair Deal Agreement” for its SRT-100 Vision™ IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th]]>https://www.globenewswire.com/news-release/2024/03/13/2845344/0/en/Sensus-Healthcare-Launches-Fair-Deal-Agreement-for-its-SRT-100-Vision-at-the-American-Academy-of-Dermatology-Annual-Meeting.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting2024-03-13T12:00:00Z<![CDATA[New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers]]>https://www.globenewswire.com/news-release/2024/02/08/2826457/0/en/Sensus-Healthcare-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results2024-02-08T21:05:57Z<![CDATA[Conference call begins at 4:30 p.m. Eastern time today]]>https://www.globenewswire.com/news-release/2024/02/08/2825980/0/en/Sensus-Healthcare-Issued-U-S-Patent-for-SRT-100-Vision-System-IG-SRT-Capabilities.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities2024-02-08T13:00:00Z<![CDATA[BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.”]]>https://www.globenewswire.com/news-release/2024/02/06/2824251/0/en/Sensus-Healthcare-Collaborates-with-CureRays-to-Provide-Oversight-to-Help-Customers-Assure-Patient-Safety-Reliability-of-Outcomes-and-Conformance-with-Regulatory-Requirements.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements2024-02-06T13:00:00Z<![CDATA[Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases]]>https://www.globenewswire.com/news-release/2024/02/01/2821925/0/en/Sensus-Healthcare-Announces-Retirement-of-Director-Samuel-O-Rear.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare Announces Retirement of Director Samuel O’Rear2024-02-01T13:00:00Z<![CDATA[BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O’Rear will not stand for reelection to the Company’s Board of Directors at the Company’s 2024 annual meeting of stockholders. Mr. O’Rear has been a Director of Sensus Healthcare since 2012.]]>https://www.globenewswire.com/news-release/2024/01/30/2819913/0/en/Sensus-Healthcare-to-Host-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-February-8-2024.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 20242024-01-30T13:00:00Z<![CDATA[BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.]]>https://www.globenewswire.com/news-release/2024/01/23/2814038/0/en/Sensus-Healthcare-Announces-Preliminary-2023-Revenue-Exceeds-23-Million.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million2024-01-23T13:00:00Z<![CDATA[Ships more than 60 SRT units in 2023To report full financial results and hold conference call on February 8th]]>https://www.globenewswire.com/news-release/2023/11/09/2777856/0/en/Sensus-Healthcare-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare Reports Third Quarter 2023 Financial Results2023-11-09T21:05:36Z<![CDATA[Revenues of $3.9 million reflect seasonality and macroeconomic conditions]]>https://www.globenewswire.com/news-release/2023/11/02/2772204/0/en/Sensus-Healthcare-to-Host-Third-Quarter-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-November-9-2023.html?f=22&fvtc=4&fvtv=55939Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 20232023-11-02T12:00:00Z<![CDATA[BOCA RATON, Fla, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.]]>